Validation of ICD‐9‐CM codes to identify gastrointestinal perforation events in administrative claims data among hospitalized rheumatoid arthritis patients
- 27 August 2011
- journal article
- research article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 20 (11) , 1150-1158
- https://doi.org/10.1002/pds.2215
Abstract
Purpose: To validate, using physician review of abstracted medical chart data as a gold standard, a claims‐based algorithm developed to identify gastrointestinal (GI) perforation cases among rheumatoid arthritis (RA) patients.Methods: Patients with established RA, aged 18 years or older with hospital admissions between January 2004 and September 2009, were selected from a large US‐hospital‐based database. An algorithm with International Classification of Diseases, Ninth Revision, Clinical Modification (ICD‐9‐CM) diagnosis codes for GI perforation and combinations of GI‐related diagnosis codes and Current Procedural Terminology (CPT‐4) procedure codes for relevant GI surgeries was used to identify potential GI perforation cases. Two senior experienced specialist physicians independently reviewed abstracted chart data and classified cases as confirmed or unconfirmed GI perforations. Positive predictive values (PPVs) to identify confirmed GI perforation were calculated and stratified by upper versus lower GI tract.Results: Overall, 86 of 92 GI perforation cases were confirmed, yielding an overall PPV of 94% (95%confidence interval [CI] = 86%–98%). PPV was 100% (95%CI = 100%–100%) for upper GI perforation (esophagus, stomach) and 91% (95%CI = 90%–97%) for lower GI perforation (small intestine, PPV = 100%; large intestine, PPV = 94%; unspecified lower GI, PPV = 89%).Conclusions: This algorithm, consisting of a combination of ICD‐9‐CM diagnosis and CPT‐4 codes, could be used in future safety studies to evaluate GI perforation risk factors in RA patients. Copyright © 2011 John Wiley & Sons, Ltd.Keywords
This publication has 33 references indexed in Scilit:
- The incidence of gastrointestinal perforations among rheumatoid arthritis patientsArthritis & Rheumatism, 2010
- Validation of claims‐based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commercially‐insured populationPharmacoepidemiology and Drug Safety, 2010
- TNF‐mediated inflammatory diseaseThe Journal of Pathology, 2007
- Serious lower gastrointestinal clinical events with nonselective NSAID or coxib useGastroenterology, 2003
- Incidence of serious upper gastrointestinal bleeding/perforation in the general population:Journal of Clinical Epidemiology, 2002
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJAMA, 2000
- An Open Study to Assess the Safety and Tolerability of Meloxicam 15 mg in Subjects with Rheumatic Disease and Mild Renal ImpairmentRheumatology, 1996
- A Long-Term Study to Evaluate the Safety and Efficacy of Meloxicam Therapy in Patients with Rheumatoid ArthritisRheumatology, 1996
- A Six-Month Double-Blind Trial to Compare the Efficacy and Safety of Meloxicam 7.5 mg Daily and Naproxen 750 mg Daily in Patients with Rheumatoid ArthritisRheumatology, 1996
- Positive Predictive Value of ICD-9 Codes in the Identification of Cases of Complicated Peptic Ulcer Disease in the Saskatchewan Hospital Automated DatabaseEpidemiology, 1996